CN101277694B - 盐酸伊立替康的新晶形 - Google Patents

盐酸伊立替康的新晶形 Download PDF

Info

Publication number
CN101277694B
CN101277694B CN2006800345941A CN200680034594A CN101277694B CN 101277694 B CN101277694 B CN 101277694B CN 2006800345941 A CN2006800345941 A CN 2006800345941A CN 200680034594 A CN200680034594 A CN 200680034594A CN 101277694 B CN101277694 B CN 101277694B
Authority
CN
China
Prior art keywords
irinotecan hydrochloride
irinotecan
crystal form
hydrochloride
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800345941A
Other languages
English (en)
Chinese (zh)
Other versions
CN101277694A (zh
Inventor
陈树平
韩平洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Singapore Pte Ltd
Original Assignee
Scinopharm Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Singapore Pte Ltd filed Critical Scinopharm Singapore Pte Ltd
Publication of CN101277694A publication Critical patent/CN101277694A/zh
Application granted granted Critical
Publication of CN101277694B publication Critical patent/CN101277694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2006800345941A 2005-09-20 2006-09-19 盐酸伊立替康的新晶形 Expired - Fee Related CN101277694B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71882705P 2005-09-20 2005-09-20
US60/718,827 2005-09-20
PCT/US2006/036437 WO2007035709A2 (en) 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride

Publications (2)

Publication Number Publication Date
CN101277694A CN101277694A (zh) 2008-10-01
CN101277694B true CN101277694B (zh) 2011-04-20

Family

ID=37889452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800345941A Expired - Fee Related CN101277694B (zh) 2005-09-20 2006-09-19 盐酸伊立替康的新晶形

Country Status (14)

Country Link
US (1) US7435818B2 (enExample)
EP (2) EP2082741A1 (enExample)
JP (1) JP5119153B2 (enExample)
KR (1) KR101150504B1 (enExample)
CN (1) CN101277694B (enExample)
AR (1) AR056082A1 (enExample)
AT (1) ATE460162T1 (enExample)
AU (1) AU2006292328B2 (enExample)
BR (1) BRPI0616308A2 (enExample)
CA (1) CA2623117C (enExample)
DE (1) DE602006012871D1 (enExample)
ES (1) ES2343204T3 (enExample)
NZ (1) NZ566807A (enExample)
WO (1) WO2007035709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012007952A1 (en) * 2010-07-12 2012-01-19 Hetero Research Foundation Novel polymorph of irinotecan hydrochloride
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CN102850363B (zh) * 2012-09-18 2013-07-10 山东罗欣药业股份有限公司 盐酸伊立替康化合物及其药物组合物
CA2909642A1 (en) * 2013-04-15 2014-10-23 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
CN105713004A (zh) * 2016-03-23 2016-06-29 杭州华东医药集团新药研究院有限公司 一种高品质盐酸伊立替康三水合物晶型的制备方法
US10919905B2 (en) * 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173648A1 (en) * 1997-10-23 2002-11-21 Smithkline Beecham Corporation Novel polymorphic forms of cipamfylline
US20050191614A1 (en) * 2000-01-07 2005-09-01 Millenium Pharmaceuticals, Inc. High-throughput formation, identification and analysis of diverse solid forms
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE60314378T2 (de) * 2002-03-01 2008-02-28 Pfizer Italia S.R.L. Kristalline polymorphe form von irinotecanhydrochlorid
CZ20022250A3 (cs) * 2002-06-27 2004-02-18 Pliva-Lachema A. S. Způsob výroby irinotekanu
KR101095382B1 (ko) 2003-02-25 2011-12-16 가부시키가이샤 야쿠르트 혼샤 이리노테칸 염산염의 결정다형의 제조방법
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
EP1846412B1 (en) * 2005-02-07 2009-10-21 Fermion Oy Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173648A1 (en) * 1997-10-23 2002-11-21 Smithkline Beecham Corporation Novel polymorphic forms of cipamfylline
US20050191614A1 (en) * 2000-01-07 2005-09-01 Millenium Pharmaceuticals, Inc. High-throughput formation, identification and analysis of diverse solid forms
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride

Also Published As

Publication number Publication date
CN101277694A (zh) 2008-10-01
EP1951235B1 (en) 2010-03-10
EP2082741A1 (en) 2009-07-29
BRPI0616308A2 (pt) 2011-06-14
ES2343204T3 (es) 2010-07-26
AU2006292328A1 (en) 2007-03-29
CA2623117A1 (en) 2007-03-29
JP2009508874A (ja) 2009-03-05
NZ566807A (en) 2011-05-27
JP5119153B2 (ja) 2013-01-16
WO2007035709A2 (en) 2007-03-29
US20070072890A1 (en) 2007-03-29
KR20080059244A (ko) 2008-06-26
AU2006292328B2 (en) 2012-12-20
EP1951235A4 (en) 2008-10-29
WO2007035709A3 (en) 2007-10-25
AR056082A1 (es) 2007-09-19
CA2623117C (en) 2013-12-10
EP1951235A2 (en) 2008-08-06
ATE460162T1 (de) 2010-03-15
US7435818B2 (en) 2008-10-14
DE602006012871D1 (de) 2010-04-22
KR101150504B1 (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
EP1487840B1 (en) Crystalline polymorphic form of irinotecan hydrochloride
CN101277694B (zh) 盐酸伊立替康的新晶形
TW202208375A (zh) ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
JP7314319B2 (ja) Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途
EP4249072A2 (en) Crystalline forms of quinolone analogs and their salts
CN114736214A (zh) 一种倍半萜衍生物、其药物组合物及其制备方法和用途
CN1913897A (zh) 新颖化合物及其组合物、制备方法和/或治疗方法
US8349863B2 (en) Crystalline polymorphic form of a camptothecin analogue
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN119569705B (zh) Ptk抑制剂a的磷酸盐及应用
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110420

Termination date: 20200919